ArticleBMJ open2026
Uptake and predictors of newborn respiratory syncytial virus (RSV) immunisation with nirsevimab in Ireland's national pilot programme: a cross-sectional study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Respiratory Pathogen Co-Detection in Hospitalized Infants with Bronchiolitis and Implementation of Universal Nirsevimab Immunoprophylaxis: A Six-Year Observational Study.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess uptake of nirsevimab, a long-acting monoclonal antibody for respiratory syncytial virus (RSV) prevention, during the first season of Ireland's Pathfinder pilot universal newborn immunisation programme and to identify socio-demographic and perinatal predictors of uptake.
designCross-sectional analysis of routinely collected programme data.
settingIreland's Mid-West region, served by University Maternity Hospital Limerick, the sole maternity and neonatal hospital for the region.
participantsInfants born 1 September 2024 to 28 February 2025. OUTCOME MEASURE: Uptake of nirsevimab before hospital discharge.
resultsOverall uptake was 89.4% (1600/1790) and did not vary by month (p=0.119); it was similar by sex (male 89.5%, female 89.2%; p=0.838). Preterm infants had higher uptake than term (96.9% vs 88.7%; p=0.001), and those admitted to the neonatal unit also had higher uptake (93.0% vs 88.4%; p=0.009). In adjusted analyses, maternal age (adjusted OR (aOR) 1.06 per year, 95% CI 1.03 to 1.09, p<0.001) and preterm birth (aOR 3.08 (95% CI 1.14 to 8.37), p=0.027) were associated with uptake. Uptake varied by maternal ethnicity: 91.5% in white Irish, 53.6% in Irish Traveller (aOR 0.13 (95% CI 0.08 to 0.23)), 79.7% in other white background (aOR 0.39 (95% CI 0.24 to 0.61)), 90.0% in black or black Irish, 98.3% in Asian or Asian Irish and 84.2% in other/mixed or prefer not to say. Although uptake among white Irish was high, they accounted for the largest absolute number of infants who did not receive nirsevimab, reflecting their predominance in the birth cohort.
conclusionsDuring the first season of Ireland's Pathfinder RSV pilot programme in the Mid-West region, nearly 90% of newborns received nirsevimab before discharge. Uptake was consistently high across months, indicating effective implementation but lower among infants of Irish Traveller and other white background mothers, highlighting the need for targeted, culturally adaptable equity strategies within a high-uptake programme. These findings may inform national and international policies and offer practical lessons for universal RSV immunisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.